| Bipolar I disorder
Abilify Maintena vs Uzedy
Side-by-side clinical, coverage, and cost comparison for bipolar i disorder.Deep comparison between: Abilify Maintena vs Uzedy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUzedy has a higher rate of injection site reactions vs Abilify Maintena based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uzedy but not Abilify Maintena, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abilify Maintena
Uzedy
At A Glance
IM injection
Every 4 weeks
Dopamine D2 partial agonist
SC injection
Every 4-8 weeks
Atypical antipsychotic
Indications
- Schizophrenia
- Bipolar I disorder
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia, Bipolar I disorder 400 mg IM injection monthly (deltoid or gluteal); reduce to 300 mg if adverse reactions occur; initiate via 1-day (two 400 mg injections + single oral aripiprazole 20 mg) or 14-day (one 400 mg injection + 14 days oral aripiprazole) protocol; CYP2D6 poor metabolizers start and maintain at 300 mg monthly.
Schizophrenia Once monthly SC injection (50 mg, 75 mg, 100 mg, or 125 mg) or once every 2 months (100 mg, 150 mg, 200 mg, or 250 mg) based on equivalent daily oral risperidone dose (2-5 mg); initiate the day after last oral dose, no loading dose required.
Bipolar I disorder Once monthly SC injection (50 mg, 75 mg, or 100 mg) as monotherapy or adjunctive therapy to lithium or valproate, based on equivalent daily oral risperidone dose (2-4 mg); once every 2 months dosing is not recommended for this indication.
Contraindications
- Known hypersensitivity to aripiprazole
- Known hypersensitivity to risperidone, its metabolite paliperidone, or any of its components
Adverse Reactions
Most common (>=5%) Increased weight, akathisia, injection site pain, sedation
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia, neutropenia, agranulocytosis, seizures, orthostatic hypotension
Postmarketing Anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, oropharyngeal spasm, pathological gambling, hiccups, blood glucose fluctuation, DRESS, fecal incontinence
Most common (>5%) Parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, pharyngolaryngeal pain
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinemia, orthostatic hypotension and syncope, leukopenia, neutropenia, agranulocytosis, seizures, dysphagia, priapism
Postmarketing Alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, diabetic ketoacidosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, sudden death, thrombocytopenia, injection site pain
Pharmacology
Aripiprazole is an atypical antipsychotic whose efficacy may be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
Risperidone is an atypical antipsychotic whose therapeutic activity may be mediated through combined dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism; clinical effect results from the combined concentrations of risperidone and its major active metabolite, 9-hydroxyrisperidone (paliperidone).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abilify Maintena
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
Uzedy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Abilify Maintena
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uzedy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abilify Maintena
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Uzedy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Cancer-Related Behavioral Health
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Movement Disorders - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Abilify MaintenaView full Abilify Maintena profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.